What's breaking now, across thousands of outlets.
In what is thought to be the first study of its kind, researchers from Cardiff University and Imperial College London examined both gut bacteria and chemicals. Their findings could support earlier diagnosis and help spot people at risk of faster decline.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
(MedPage Today) -- It's traditionally been frowned upon for us doctors to talk with patients about voting. But at a time of growing crisis in healthcare, clinicians now face an important decision in…
Let's look into the health issue that will keep Hurts from the field in 2026.
Not all creativity may draw on the same bodily state. In a study that tracked students’ hearts for five days, calmer physiological states went with more original drawings but less original verbal…
Research at the University of Missouri could lead to new therapies for people with amyotrophic lateral sclerosis (ALS) and other motor neuron diseases.
Months after the FDA rejected its treatment for a rare light-sensitivity disease, the biotech claimed success in a Phase 3 trial and now plans to re-engage regulators.
Between 1999 and 2020, breast cancer mortality declined across rural and urban populations, but by 2005, mortality among rural patients surpassed that of urban patients and after 2013 remained…
